In the landscape of modern drug discovery, a quiet revolution is unfolding in the archives of pathology labs. For decades, the life cycle of a tissue slide was linear and finite: a pathologist would examine a glass specimen, record a diagnostic conclusion, and archive the slide in a storage box, where it would likely remain untouched. Today, that "one-way street" is being transformed into a rich, multidimensional data highway.
Driven by the rapid adoption of digital pathology—a transition accelerated by the pandemic—researchers are now leveraging archived tissue and digitized slides to extract unprecedented insights. This shift is not merely about technological convenience; it is a fundamental reimagining of preclinical research that promises to drastically reduce the reliance on animal testing, aligning scientific practice with both ethical imperatives and evolving regulatory landscapes.
Main Facts: The Shift from Report to Data
Historically, the "pathology endpoint" was a static document—a report summarizing the presence or absence of a biological reaction. Today, that endpoint has evolved into high-resolution pixels. As Aleksandra Zuraw, DVM, PhD, a veterinary pathologist at Charles River Laboratories, aptly notes, "Before, the pathology endpoint was just a report. Now you have the digitized slide, which is data."
By digitizing these slides, researchers can pair visual information with molecular measurements to train artificial intelligence models. These models can recognize complex patterns that are invisible to the human eye, linking morphological changes in tissue to underlying molecular pathways. A single slide, once viewed only for its primary purpose, now serves as an infinite resource for secondary research, allowing scientists to ask—and answer—new questions without the need for additional animal models.
A Chronology of Progress: From Pandemic Necessity to Regulatory Mandate
The trajectory of digital pathology has moved from a "nice-to-have" remote work tool to a cornerstone of modern scientific methodology.
- 2020–2022: The Pandemic Catalyst: Widespread lockdowns forced pathology departments globally to embrace digital slide scanning to maintain operational continuity. This necessity proved the viability of remote diagnostic workflows.
- 2022: The FDA Modernization Act 2.0: A legislative landmark, this act signaled a paradigm shift in the United States, allowing for non-animal methods to support human clinical trial applications, effectively stripping away the legal requirement for animal-only data.
- 2024: Industry Commitment: Charles River Laboratories launched its Alternative Methods Advancement Project, signaling a significant industry-wide investment in reducing animal reliance through innovative data use.
- 2025: Global Standardization: The OECD issued critical guidance on sample collection for "omics" analysis, providing a framework for how preserved tissue can be utilized for deep molecular investigation, such as gene expression and protein analysis.
- 2026: The Roadmap to the Future: The FDA released a roadmap aimed at reducing animal testing in preclinical safety studies. The agency’s stated goal is to transition animal studies from the "default" method to the "exception" over the next three to five years, positioning New Approach Methodologies (NAMs) as the standard.
Supporting Data: Maximizing Every Animal
One of the most promising applications of this digital transformation is the implementation of "virtual control groups." In standard toxicology studies, a significant number of animals are utilized purely as control groups to establish a baseline for comparison.
"Control animals are always a big fraction of every study," Dr. Zuraw explains. By utilizing high-quality historical data—digitized and standardized—researchers can replace a portion of these live control animals with "virtual" counterparts. This is not a task performed lightly; it requires rigorous validation to ensure that historical conditions and modern study parameters are sufficiently comparable. Charles River’s team is currently building the infrastructure to provide these matched data sets, ensuring that virtual controls can be used with high statistical confidence.
Furthermore, the utilization of Formalin-Fixed, Paraffin-Embedded (FFPE) blocks is becoming a gold mine for retrospective research. When researchers encounter an unexpected question after a study concludes, they no longer need to initiate a new, costly, and ethically complex animal study. Instead, they can return to the archived FFPE blocks, perform molecular assays on the existing tissue, and preserve the "study context" that links the tissue to the original dosing and outcome data.
Emerging Technologies: Beyond the Glass Slide
The evolution of the field is supported by a suite of cutting-edge technologies that are fundamentally changing the "input" of pathology:
Virtual Staining
Virtual staining is perhaps the most disruptive innovation currently entering the workflow. Traditionally, tissue must be physically stained to reveal specific structures for a microscope. Virtual staining uses software to generate these visual markers from unstained, scanned tissue sections. This process not only saves time and reagents but also allows for the application of multiple "virtual stains" to the same tissue section, providing layers of data that would be physically impossible to achieve with traditional chemistry.
Molecular Prediction from H&E Slides
Hematoxylin and Eosin (H&E) staining is the standard of clinical practice. New AI models are now capable of predicting molecular states—such as specific genetic mutations—directly from H&E-stained images. This capability effectively turns every standard histology slide into a molecular diagnostic tool, without requiring the additional expense of genomic sequencing for every single sample.
Official Responses and Regulatory Outlook
The regulatory environment has shifted from cautious skepticism to proactive encouragement. The FDA’s move to make NAMs the default represents a historic acknowledgement that traditional animal models are not always the most predictive or efficient tools for human safety assessment.
However, the transition requires a "precedent-setting" period. As Dr. Zuraw emphasizes, "You still need enough early adopters to generate precedent." Regulatory bodies are looking for proof-of-concept studies where these methods have successfully predicted toxicity or efficacy. By demonstrating the reliability of virtual controls and molecular imaging in real-world studies, early adopters are creating a "snowball effect" that will allow smaller laboratories and research institutions to adopt these methods without having to "reinvent the wheel."
Implications for the Future of Science
The implications of this digital turn are profound, spanning ethics, economics, and scientific precision:
- Ethical Advancement: The most immediate impact is the reduction of animal life used in preclinical research. As the industry moves closer to the "3Rs" (Replacement, Reduction, and Refinement), the ability to extract more data from existing animals is the most direct path to the replacement of animal models.
- Economic Efficiency: While the upfront investment in digital infrastructure (scanners, AI platforms, and data management systems) is significant, the long-term reduction in animal housing, maintenance, and study duration offers a compelling ROI for pharmaceutical companies.
- Scientific Depth: By mining archived tissue, researchers can conduct longitudinal studies that were previously impossible. We are entering an era where we can revisit the results of a 2020 study with 2026 technology, potentially uncovering signals of toxicity or therapeutic efficacy that were simply invisible at the time of the original analysis.
- Standardization and Reproducibility: Digital data is inherently more reproducible than physical glass slides, which can fade or break over time. A digital library of tissue provides a stable, searchable, and shareable foundation for global research collaboration.
As the industry moves toward this digital-first future, the role of the pathologist is evolving. They are becoming data scientists and curators of biological information, tasked not just with identifying morphology, but with interpreting the complex, data-rich patterns generated by AI.
The "snowball effect" described by Dr. Zuraw is already in motion. As labs integrate these tools into their daily workflows, the traditional, wasteful approach to tissue management will look increasingly like a relic of the past. The future of drug discovery lies not in the creation of more animal models, but in the intelligent, ethical, and digital extraction of knowledge from the vast archives we have already created.
About the Author
